CD4 News and Research

RSS

Natural compound can virtually eradicate HIV in infected culture cells

A new study by scientists on the Florida campus of The Scripps Research Institute shows, in cell culture, a natural compound can virtually eliminate human immunodeficiency virus (HIV) in infected cells. The compound defines a novel class of HIV anti-viral drugs endowed with the capacity to repress viral replication in acutely and chronically infected cells.

20 Jul 2012

Researchers identify new behavior for the human macrophage

Researchers at the Institute of Human Virology of the University of Maryland School of Medicine have identified a new behavior for the human macrophage that provides new explanations for several features of HIV biology, including how the virus persists within the body indefinitely, how quiescently infected CD4+ T-cells arise, and how the infection leads to depletion of CD4+ T-cells.

19 Jul 2012

Helper T cells may be frontline warriors when battling hepatitis A infection

Helper cells traditionally thought to only assist killer white blood cells may be the frontline warriors when battling hepatitis A infection. These are the findings from a Nationwide Children's Hospital study appearing in a recent issue of the Journal of Experimental Medicine.

17 Jul 2012

SRI receives NIAID grant to develop HIV vaccine

The Scripps Research Institute has been awarded a grant expected to total more than $77 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2012

Sleep loss mirrors stress affects on immune system

Acute sleep loss affects the immune system in a similar way to stress, researchers report.

10 Jul 2012

Methylation provides signal of unique mix of leukocytes

When a person is sick, there is a tell-tale sign in their blood: a different mix of the various types of immune cells called leukocytes. A group of scientists at several institutions including Brown University has discovered a way to determine that mix from the DNA in archival or fresh blood samples, potentially providing a practical new technology not only for medical research but also for clinical diagnosis and treatment monitoring of ailments including some cancers.

10 Jul 2012

Scientists use antibody injections to rapidly reverse onset of Type I diabetes in mice

Scientists at the University of North Carolina School of Medicine have used injections of antibodies to rapidly reverse the onset of Type I diabetes in mice genetically bred to develop the disease. Moreover, just two injections maintained disease remission indefinitely without harming the immune system.

6 Jul 2012

HIV therapy: Interview with Joël Crouzet, CEO of InnaVirVax

HIV therapy has traditionally been associated with antiretrovirals, which considerably reduce the amount of virus present in the blood to nearly undetectable levels.

29 Jun 2012

SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

27 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.

19 Jun 2012

Subtype of CD4-positive immune cells in the gut may influence HIV infection outcome

The findings of a new study in monkeys may help clarify why some people infected with HIV are better able to control the virus. They also may pinpoint a target for treatment during early HIV infection aimed at increasing the supply of certain immune cells in the gut, which the study shows could be an important factor in limiting HIV growth in cells throughout the body.

11 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

Pre-exposure preventive treatment may be effective against suspected HIV

While immediate postexposure treatment for suspected HIV is critical, pre-exposure preventive treatment is a newer method that may be effective for people in high-risk groups, states a review of evidence published in CMAJ (Canadian Medical Association Journal).

29 May 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

Novel stem cell transplantation holds promise for HIV prevention

UC Davis Health System researchers are a step closer to launching human clinical trials involving the use of an innovative stem cell therapy to fight the virus that causes AIDS.

3 May 2012

Blog posts report on International Treatment as Prevention conference in Vancouver

Two separate posts in the Center for Global Health Policy's "Science Speaks" blog report on the International Treatment as Prevention conference in Vancouver. The first post recaps an update from Stephen Becker of the Bill & Melinda Gates Foundation on Tuesday "about the Foundation's treatment optimization activities," writing, "According to Becker, the Foundation acknowledges that treatment will be at the center of HIV prevention efforts, but 'no amount of treatment will obviate the need for primary prevention modalities.'"

27 Apr 2012

Poverty linked to HIV infection among heterosexuals living in inner-city neighborhoods

In a groundbreaking study published last year, scientists reported that effective treatment with HIV medications not only restores health and prolongs life in many HIV-infected patients, but also curtails transmission to sexual partners up to ninety-seven percent. However, a new study by UCSF scientists shows that lack of basic living needs severely undercuts these advances in impoverished men.

27 Apr 2012

Researchers discover novel genetic mechanism of idiopathic CD4 lymphopenia

Researchers at National Jewish Health have discovered a novel genetic mechanism of immune deficiency. Magdalena M. Gorska, MD, PhD, and Rafeul Alam, MD, PhD, identified a mutation in Unc119 that causes immunodeficiency known as idiopathic CD4 lymphopenia.

21 Apr 2012

Ohio AIDS advocates, patients protest against rationing of lifesaving HIV medicines

A group of Ohio AIDS advocates, patients and medical providers hosted a protest in Columbus today in conjunction with a public hearing held by the Ohio Department of Health (ODH) and its Director, Theodore E. Wymyslo, M.D., on proposed rule changes that would restrict access to lifesaving AIDS drugs for low-income Ohioans based on medical criteria.

6 Apr 2012

Women with HIV superinfection have more potent antibody responses

Women who have been infected by two different strains of HIV from two different sexual partners - a condition known as HIV superinfection - have more potent antibody responses that block the replication of the virus compared to women who've only been infected once. These findings, by researchers at Fred Hutchinson Cancer Research Center in Seattle, are published online March 29 in PLoS Pathogens.

30 Mar 2012